Shanghai MicuRx Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Shanghai MicuRx Pharmaceutical's earnings have been declining at an average annual rate of -29.4%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 53.1% per year.
Key information
-29.4%
Earnings growth rate
-11.9%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 53.1% |
| Return on equity | -82.4% |
| Net Margin | -389.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai MicuRx Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 120 | -468 | 182 | 386 |
| 30 Jun 24 | 109 | -497 | 178 | 415 |
| 31 Mar 24 | 107 | -467 | 184 | 386 |
| 31 Dec 23 | 91 | -421 | 169 | 345 |
| 30 Sep 23 | 82 | -291 | 159 | 238 |
| 30 Jun 23 | 70 | -238 | 161 | 181 |
| 31 Mar 23 | 55 | -225 | 149 | 161 |
| 31 Dec 22 | 48 | -220 | 146 | 150 |
| 30 Sep 22 | 37 | -275 | 144 | 180 |
| 30 Jun 22 | 28 | -247 | 134 | 160 |
| 31 Mar 22 | 18 | -242 | 134 | 159 |
| 31 Dec 21 | 8 | -226 | 124 | 152 |
| 31 Dec 20 | 0 | -86 | 42 | 53 |
| 31 Dec 19 | 0 | -115 | 33 | 94 |
| 31 Dec 18 | 1 | -150 | 26 | 141 |
Quality Earnings: 688373 is currently unprofitable.
Growing Profit Margin: 688373 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688373 is unprofitable, and losses have increased over the past 5 years at a rate of 29.4% per year.
Accelerating Growth: Unable to compare 688373's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688373 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688373 has a negative Return on Equity (-82.44%), as it is currently unprofitable.